| 1 | Thymomas With Pleural Metastases: When Less is More | 1.3 | 0 | Citations (PDF) |
| 2 | MIG6 Mediates Adaptive and Acquired Resistance to ALK/ROS1 Fusion Kinase Inhibition through EGFR Bypass Signaling | 1.2 | 9 | Citations (PDF) |
| 3 | Effects of
KRAS
Genetic Interactions on Outcomes in Cancers of the Lung, Pancreas, and Colorectum | 0.6 | 7 | Citations (PDF) |
| 4 | Genomic Characterization and Clinical Outcomes of Patients with Peritoneal Metastases from the AACR GENIE Biopharma Collaborative Colorectal Cancer Registry | 2.1 | 4 | Citations (PDF) |
| 5 | Single-Cell Sequencing Illuminates Thymic Development: An Updated Framework for Understanding Thymic Epithelial Tumors | 2.5 | 9 | Citations (PDF) |
| 6 | Tumor-Agnostic Genomic and Clinical Analysis of
BRAF
Fusions Identifies Actionable Targets | 4.5 | 13 | Citations (PDF) |
| 7 | Annotated test-retest dataset of lung cancer CT scan images reconstructed at multiple imaging parameters | 3.8 | 6 | Citations (PDF) |
| 8 | Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer | 6.8 | 136 | Citations (PDF) |
| 9 | Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in
EGFR
-Mutant Lung Adenocarcinomas | 4.5 | 1 | Citations (PDF) |
| 10 | Early Changes in Circulating Cell-Free
KRAS
G12C Predict Response to Adagrasib in KRAS Mutant Non–Small Cell Lung Cancer Patients | 4.5 | 23 | Citations (PDF) |
| 11 | The GENIE BPC NSCLC Cohort: A Real-World Repository Integrating Standardized Clinical and Genomic Data for 1,846 Patients with Non–Small Cell Lung Cancer | 4.5 | 34 | Citations (PDF) |
| 12 | Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non–Small Cell Lung Cancer | 4.5 | 36 | Citations (PDF) |
| 13 | Analysis and Visualization of Longitudinal Genomic and Clinical Data from the AACR Project GENIE Biopharma Collaborative in cBioPortal | 2.6 | 887 | Citations (PDF) |
| 14 | CT Radiomic Features for Predicting Resectability and TNM Staging in Thymic Epithelial Tumors | 2.6 | 22 | Citations (PDF) |
| 15 | Smarca4
Inactivation Promotes Lineage-Specific Transformation and Early Metastatic Features in the Lung | 6.8 | 112 | Citations (PDF) |
| 16 | The Use of Sunitinib as Maintenance Therapy in a Pediatric Patient With a Poorly Differentiated Thymic Carcinoma | 0.5 | 0 | Citations (PDF) |
| 17 | Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patientsCell, 2022, 185, 563-575.e11 | 23.4 | 605 | Citations (PDF) |
| 18 | Encorafenib Plus Binimetinib in Patients with
BRAF
V600
-Mutant Non-Small Cell Lung Cancer: Phase II PHAROS Study Design | 1.7 | 24 | Citations (PDF) |
| 19 | Validation of a Population-Based Data Source to Examine National Cancer Clinical Trial Participation | 5.2 | 11 | Citations (PDF) |
| 20 | One committee to review it all: A single, multi-disciplinary COVID-19 research committee | 1.1 | 1 | Citations (PDF) |
| 21 | Adagrasib in Non–Small-Cell Lung Cancer Harboring a
KRAS
G12C
Mutation | 26.4 | 978 | Citations (PDF) |
| 22 | Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline | 12.4 | 121 | Citations (PDF) |
| 23 | Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline | 12.4 | 110 | Citations (PDF) |
| 24 | Genomic Landscapes and Hallmarks of Mutant RAS in Human Cancers | 2.6 | 37 | Citations (PDF) |
| 25 | Clinical Trial Participation Among Older Adult Medicare Fee-for-Service Beneficiaries With Cancer | 10.9 | 23 | Citations (PDF) |
| 26 | Deep Learning to Estimate RECIST in Patients with NSCLC Treated with PD-1 Blockade | 6.8 | 66 | Citations (PDF) |
| 27 | Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C–Mutant Non–Small Cell Lung Cancer | 4.5 | 122 | Citations (PDF) |
| 28 | KRAS
G12C Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung Adenocarcinoma | 4.5 | 37 | Citations (PDF) |
| 29 | Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer with
EGFR
Exon 20 Insertion Mutations from a Phase I/II Trial | 6.8 | 211 | Citations (PDF) |
| 30 | A Genomic-Pathologic Annotated Risk Model to Predict Recurrence in Early-Stage Lung Adenocarcinoma | 6.1 | 99 | Citations (PDF) |
| 31 | Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update | 12.4 | 280 | Citations (PDF) |
| 32 | Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with
EGFR
Exon 20 Insertions | 4.5 | 57 | Citations (PDF) |
| 33 | Acquired Resistance to KRAS
G12C
Inhibition in Cancer | 26.4 | 1,206 | Citations (PDF) |
| 34 | Translating inspiration from COVID-19 vaccine trials to innovations in clinical cancer research | 28.4 | 1 | Citations (PDF) |
| 35 | Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions | 1.8 | 25 | Citations (PDF) |
| 36 | Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer | 10.9 | 268 | Citations (PDF) |
| 37 | Diverse alterations associated with resistance to KRAS(G12C) inhibition | 30.6 | 462 | Citations (PDF) |
| 38 | Immune biomarkers and response to checkpoint inhibition of BRAFV600 and BRAF non-V600 altered lung cancers | 4.1 | 23 | Citations (PDF) |
| 39 | Efficacy of Platinum/Pemetrexed Combination Chemotherapy in ALK-Positive NSCLC Refractory to Second-Generation ALK Inhibitors | 1.5 | 68 | Citations (PDF) |
| 40 | Long-term, disease-specific outcomes of thymic malignancies presenting with de novo pleural metastasis | 2.2 | 28 | Citations (PDF) |
| 41 | SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas | 1.5 | 304 | Citations (PDF) |
| 42 | The Genomic Landscape of
SMARCA4
Alterations and Associations with Outcomes in Patients with Lung Cancer | 4.5 | 284 | Citations (PDF) |
| 43 | Effect of Osimertinib and Bevacizumab on Progression-Free Survival for Patients With Metastatic EGFR-Mutant Lung Cancers | 10.9 | 119 | Citations (PDF) |
| 44 | MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by
ROS1
Fusions | 4.5 | 47 | Citations (PDF) |
| 45 | Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study | 15.9 | 60 | Citations (PDF) |
| 46 | Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update | 12.4 | 365 | Citations (PDF) |
| 47 | Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in
EGFR
-Mutant Lung Cancer | 4.5 | 373 | Citations (PDF) |
| 48 | Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with
EGFR
-Mutant Lung Cancers | 4.5 | 327 | Citations (PDF) |
| 49 | Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes | 1.5 | 407 | Citations (PDF) |
| 50 | Lessons learned from routine, targeted assessment of liquid biopsies for EGFR T790M resistance mutation in patients with EGFR mutant lung cancers | 1.7 | 13 | Citations (PDF) |
| 51 | Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial | 16.1 | 336 | Citations (PDF) |
| 52 | Comprehensive Next-Generation Sequencing Unambiguously Distinguishes Separate Primary Lung Carcinomas From Intrapulmonary Metastases: Comparison with Standard Histopathologic Approach | 4.5 | 103 | Citations (PDF) |
| 53 | Frequency and outcomes of brain metastases in patients with HER2‐mutant lung cancers | 2.7 | 90 | Citations (PDF) |
| 54 | Systemic Therapy for Locally Advanced and Metastatic Non–Small Cell Lung Cancer | 14.4 | 986 | Citations (PDF) |
| 55 | Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers | 1.5 | 99 | Citations (PDF) |
| 56 | Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib | 8.0 | 374 | Citations (PDF) |
| 57 | Exceptional responders with invasive mucinous adenocarcinomas: a phase 2 trial of bortezomib in patients with KRAS G12D-mutant lung cancers | 0.8 | 33 | Citations (PDF) |
| 58 | Tumor mutational load predicts survival after immunotherapy across multiple cancer types | 14.1 | 3,654 | Citations (PDF) |
| 59 | A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers | 3.2 | 119 | Citations (PDF) |
| 60 | Concurrent Alterations in EGFR-Mutant Lung Cancers Associated with Resistance to EGFR Kinase Inhibitors and Characterization of MTOR as a Mediator of Resistance | 4.5 | 248 | Citations (PDF) |
| 61 | Effects of Co-occurring Genomic Alterations on Outcomes in Patients with
KRAS
-Mutant Non–Small Cell Lung Cancer | 4.5 | 458 | Citations (PDF) |
| 62 | Twice weekly pulse and daily continuous‐dose erlotinib as initial treatment for patients with epidermal growth factor receptor–mutant lung cancers and brain metastases | 2.7 | 27 | Citations (PDF) |
| 63 | Acquired
ALK
and
RET
Gene Fusions as Mechanisms of Resistance to Osimertinib in
EGFR
-Mutant Lung Cancers | 1.1 | 84 | Citations (PDF) |
| 64 | Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non–Small-Cell Lung Cancer | 12.4 | 998 | Citations (PDF) |
| 65 | Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing | 12.4 | 1,325 | Citations (PDF) |
| 66 | Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study | 16.1 | 748 | Citations (PDF) |
| 67 | Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC | 1.5 | 75 | Citations (PDF) |
| 68 | YES1
amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics | 5.2 | 53 | Citations (PDF) |
| 69 | Targeting ALK: Precision Medicine Takes on Drug Resistance | 6.8 | 497 | Citations (PDF) |
| 70 | Renal cyst formation in patients treated with crizotinib for non-small cell lung cancer—Incidence, radiological features and clinical characteristics | 1.8 | 26 | Citations (PDF) |
| 71 | Optimizing Treatment for Patients With Anaplastic Lymphoma Kinase‐Positive Lung Cancer | 2.8 | 26 | Citations (PDF) |
| 72 | Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients | 22.6 | 3,185 | Citations (PDF) |
| 73 | Diagnosis and Treatment of Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer | 1.5 | 56 | Citations (PDF) |
| 74 | Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies | 6.8 | 609 | Citations (PDF) |
| 75 | Patterns of initial and intracranial failure in metastatic EGFR-mutant non-small cell lung cancer treated with erlotinib | 1.8 | 55 | Citations (PDF) |
| 76 | Investigation of patterns of nodal metastases in BRAF mutant lung cancer | 1.8 | 11 | Citations (PDF) |
| 77 | Radiogenomic evaluation of lung cancer — Are there imaging characteristics associated with lung adenocarcinomas harboring BRAF mutations? | 1.2 | 17 | Citations (PDF) |
| 78 | A Phase 1/2 Trial of Ruxolitinib and Erlotinib in Patients with EGFR -Mutant Lung Adenocarcinomas with Acquired Resistance to Erlotinib | 1.5 | 54 | Citations (PDF) |
| 79 | CMET-08. PROGNOSTIC FACTORS AND OUTCOMES OF PATIENTS WITH CENTRAL NERVOUS SYSTEM (CNS) METASTATIC ALK-REARRANGED NON-SMALL CELL LUNG CANCER (NSCLC) | 0.9 | 0 | Citations (PDF) |
| 80 | Identification and Functional Characterization of
EGFR
V769M, a Novel Germline Variant Associated With Multiple Lung Adenocarcinomas | 1.1 | 13 | Citations (PDF) |
| 81 | Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update | 12.4 | 548 | Citations (PDF) |
| 82 | OncoKB: A Precision Oncology Knowledge Base | 1.1 | 2,009 | Citations (PDF) |
| 83 | Expression of PD-L1 and other immunotherapeutic targets in thymic epithelial tumors | 1.5 | 67 | Citations (PDF) |
| 84 | Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial | 16.1 | 417 | Citations (PDF) |
| 85 | Clinical Application of Picodroplet Digital PCR Technology for Rapid Detection of EGFR T790M in Next-Generation Sequencing Libraries and DNA from Limited Tumor Samples | 1.9 | 22 | Citations (PDF) |
| 86 | Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial | 16.1 | 432 | Citations (PDF) |
| 87 | Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial | 16.1 | 624 | Citations (PDF) |
| 88 | Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes | 2.1 | 149 | Citations (PDF) |
| 89 | A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with
ROS1
-Rearranged Lung Cancer | 4.5 | 163 | Citations (PDF) |
| 90 | Detection of T790M, the Acquired Resistance
EGFR
Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses | 4.5 | 352 | Citations (PDF) |
| 91 | Massively Parallel Sequencing Identifies Recurrent Mutations in TP53 in Thymic Carcinoma Associated with Poor Prognosis | 1.5 | 64 | Citations (PDF) |
| 92 | Non–Small Cell Lung Cancer, Version 6.2015 | 2.6 | 347 | Citations (PDF) |
| 93 | Epidermal growth factor receptor exon 20 insertions in advanced lung adenocarcinomas: Clinical outcomes and response to erlotinib | 2.7 | 201 | Citations (PDF) |
| 94 | Beyond “Second-Line” in Non–Small Cell Lung Cancer: Therapy and Supportive Care | 4.5 | 2 | Citations (PDF) |
| 95 | Differences in the survival of patients with recurrent versus de novo metastatic KRAS‐mutant and EGFR‐mutant lung adenocarcinomas | 2.7 | 15 | Citations (PDF) |
| 96 | Prognostic Impact of KRAS Mutation Subtypes in 677 Patients with Metastatic Lung Adenocarcinomas | 1.5 | 127 | Citations (PDF) |
| 97 | Acquired Resistance ofEGFR-Mutant Lung Cancer to a T790M-Specific EGFR Inhibitor | 10.9 | 239 | Citations (PDF) |
| 98 | Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor–Resistant
EGFR
-Mutant Lung Cancer with and without T790M Mutations | 6.8 | 362 | Citations (PDF) |
| 99 | Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing | 8.0 | 195 | Citations (PDF) |
| 100 | Clinical Characteristics and Course of 63 Patients with BRAF Mutant Lung Cancers | 1.5 | 121 | Citations (PDF) |
| 101 | Prognostic Significance of Adenocarcinoma In Situ, Minimally Invasive Adenocarcinoma, and Nonmucinous Lepidic Predominant Invasive Adenocarcinoma of the Lung in Patients With Stage I Disease | 2.3 | 242 | Citations (PDF) |
| 102 | Associations Between Mutations and Histologic Patterns of Mucin in Lung Adenocarcinoma | 2.3 | 156 | Citations (PDF) |
| 103 | Ceritinib in
ALK
-Rearranged Non–Small-Cell Lung Cancer | 26.4 | 1,446 | Citations (PDF) |
| 104 | Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer | 26.4 | 1,892 | Citations (PDF) |
| 105 | Are there imaging characteristics associated with lung adenocarcinomas harboring ALK rearrangements? | 1.8 | 63 | Citations (PDF) |
| 106 | Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study | 16.1 | 681 | Citations (PDF) |
| 107 | Therapeutic Strategies Utilized in the Setting of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors | 4.5 | 78 | Citations (PDF) |
| 108 | Erlotinib Versus Radiation Therapy for Brain Metastases in Patients With EGFR-Mutant Lung Adenocarcinoma | 1.3 | 95 | Citations (PDF) |
| 109 | Unsuspected Collision of Synchronous Lung Adenocarcinomas: A Potential Cause of Aberrant Driver Mutation Profiles | 1.5 | 8 | Citations (PDF) |
| 110 | Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas | 2.7 | 163 | Citations (PDF) |
| 111 | KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma | 3.8 | 116 | Citations (PDF) |
| 112 | Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer | 8.7 | 529 | Citations (PDF) |
| 113 | Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with
EGFR
-Mutant Lung Cancers | 4.5 | 2,393 | Citations (PDF) |
| 114 | Characteristics of Lung Cancers Harboring
NRAS
Mutations | 4.5 | 145 | Citations (PDF) |
| 115 | ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS: An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer | 4.5 | 593 | Citations (PDF) |
| 116 | New Pathologic Classification of Lung Cancer: Relevance for Clinical Practice and Clinical Trials | 12.4 | 536 | Citations (PDF) |
| 117 | Crizotinib versus Chemotherapy in Advanced
ALK
-Positive Lung Cancer | 26.4 | 3,416 | Citations (PDF) |
| 118 | Thymomas and Thymic Carcinomas | 2.6 | 104 | Citations (PDF) |
| 119 | Local Therapy with Continued EGFR Tyrosine Kinase Inhibitor Therapy as a Treatment Strategy in EGFR-Mutant Advanced Lung Cancers That Have Developed Acquired Resistance to EGFR Tyrosine Kinase Inhibitors | 1.5 | 343 | Citations (PDF) |
| 120 | Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancers | 2.6 | 94 | Citations (PDF) |
| 121 | Molecular Epidemiology of
EGFR
and
KRAS
Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related
KRAS
-Mutant Cancers | 4.5 | 626 | Citations (PDF) |
| 122 | Non–Small Cell Lung Cancer | 2.6 | 331 | Citations (PDF) |
| 123 | Distinct Clinical Course of EGFR -Mutant Resected Lung Cancers: Results of Testing of 1118 Surgical Specimens and Effects of Adjuvant Gefitinib and Erlotinib | 1.5 | 173 | Citations (PDF) |
| 124 | ALK-Rearranged Lung Cancer: Adenosquamous Lung Cancer Masquerading as Pure Squamous Carcinoma | 1.5 | 52 | Citations (PDF) |
| 125 | Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study | 16.1 | 1,234 | Citations (PDF) |
| 126 | Coexistence of
PIK3CA
and Other Oncogene Mutations in Lung Adenocarcinoma–Rationale for Comprehensive Mutation Profiling | 1.2 | 206 | Citations (PDF) |
| 127 | Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor
BRAF
gene mutations but lack mutations in
KRAS, NRAS,
or
MEK1 | 5.2 | 438 | Citations (PDF) |
| 128 | Driver mutations determine survival in smokers and never‐smokers with stage IIIB/IV lung adenocarcinomas | 2.7 | 60 | Citations (PDF) |
| 129 | Multidisciplinary Management of Thymic Carcinoma | 4.5 | 2 | Citations (PDF) |
| 130 | Subtyping of Non-small Cell Lung Carcinoma: A Comparison of Small Biopsy and Cytology Specimens | 1.5 | 127 | Citations (PDF) |
| 131 | Frequency of EGFR and KRAS Mutations in Lung Adenocarcinomas in African Americans | 1.5 | 137 | Citations (PDF) |
| 132 | Management and Outcomes of Relapse After Treatment for Thymoma and Thymic Carcinoma | 2.6 | 53 | Citations (PDF) |
| 133 | Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with EGFR-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Clinical Trial Design | 4.5 | 416 | Citations (PDF) |
| 134 | Impact of proposed IASLC/ATS/ERS classification of lung adenocarcinoma: prognostic subgroups and implications for further revision of staging based on analysis of 514 stage I cases | 3.8 | 965 | Citations (PDF) |
| 135 | Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation | 4.5 | 596 | Citations (PDF) |
| 136 | Phase I/II Trial of Cetuximab and Erlotinib in Patients with Lung Adenocarcinoma and Acquired Resistance to Erlotinib | 4.5 | 117 | Citations (PDF) |
| 137 | International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma | 1.5 | 4,669 | Citations (PDF) |
| 138 | Suitability of Thoracic Cytology for New Therapeutic Paradigms in Non-small Cell Lung Carcinoma: High Accuracy of Tumor Subtyping and Feasibility of EGFR and KRAS Molecular Testing | 1.5 | 235 | Citations (PDF) |
| 139 | Insulin-Like Growth Factor-1 Receptor Expression in Thymic Malignancies | 1.5 | 63 | Citations (PDF) |
| 140 | Pack‐years of cigarette smoking as a prognostic factor in patients with stage IIIB/IV nonsmall cell lung cancer | 2.7 | 115 | Citations (PDF) |
| 141 | Impact of Epidermal Growth Factor Receptor and KRAS Mutations on Clinical Outcomes in Previously Untreated Non–Small Cell Lung Cancer Patients: Results of an Online Tumor Registry of Clinical Trials | 4.5 | 386 | Citations (PDF) |
| 142 | Evaluating Variability in Tumor Measurements from Same-day Repeat CT Scans of Patients with Non–Small Cell Lung Cancer | 6.7 | 314 | Citations (PDF) |
| 143 | Comparison of patterns of relapse in thymic carcinoma and thymoma | 2.2 | 140 | Citations (PDF) |
| 144 | Randomized Phase II Study of Pulse Erlotinib Before or After Carboplatin and Paclitaxel in Current or Former Smokers With Advanced Non–Small-Cell Lung Cancer | 12.4 | 55 | Citations (PDF) |
| 145 | KRAS mutational testing in the selection of patients for EGFR-targeted therapies | 1.8 | 17 | Citations (PDF) |
| 146 | EGFR Mutations in Lung Adenocarcinomas | 1.9 | 203 | Citations (PDF) |
| 147 | EGFR Mutant Lung Adenocarcinomas in Patients with Germline BRCA Mutations | 1.5 | 17 | Citations (PDF) |
| 148 | Lung Adenocarcinoma: Modification of the 2004 WHO Mixed Subtype to Include the Major Histologic Subtype Suggests Correlations Between Papillary and Micropapillary Adenocarcinoma Subtypes, EGFR Mutations and Gene Expression Analysis | 2.3 | 358 | Citations (PDF) |
| 149 | MET
amplification occurs with or without
T790M
mutations in
EGFR
mutant lung tumors with acquired resistance to gefitinib or erlotinib | 5.2 | 1,613 | Citations (PDF) |
| 150 | A phase 2 study of TZT-1027, administered weekly to patients with advanced non-small cell lung cancer following treatment with platinum-based chemotherapy | 1.8 | 59 | Citations (PDF) |
| 151 | Use of Cigarette-Smoking History to Estimate the Likelihood of Mutations in Epidermal Growth Factor Receptor Gene Exons 19 and 21 in Lung Adenocarcinomas | 12.4 | 208 | Citations (PDF) |
| 152 | Molecular On/Off Switch | 12.4 | 11 | Citations (PDF) |
| 153 | KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib | 4.6 | 1,373 | Citations (PDF) |
| 154 | Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain | 4.6 | 3,151 | Citations (PDF) |
| 155 | Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non–Small Cell Lung Cancer | 12.4 | 11 | Citations (PDF) |
